City Therapeutics, Inc. Common Stock Total Assets
City Therapeutics, Inc. Common Stock total assets. Based on the latest financial reports, City Therapeutics, Inc. Common Stock (CTY) holds total assets worth $208.61 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see City Therapeutics, Inc. Common Stock (CTY) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of City Therapeutics, Inc. Common Stock (2005–2025)
Total assets of City Therapeutics, Inc. Common Stock from 2005 to 2025. This chart illustrates how City Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See CTY share price today for real-time trading data and today's change.
City Therapeutics, Inc. Common Stock - Asset Composition Analysis
City Therapeutics, Inc. Common Stock Total Assets Breakdown (December 2025)
City Therapeutics, Inc. Common Stock total assets breakdown as of December 2025. City Therapeutics, Inc. Common Stock's total assets of $208.61 Million consist of 78.0% current assets and 22.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 75.3% |
| Accounts Receivable | $1.21 Million | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how City Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore City Therapeutics, Inc. Common Stock current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: City Therapeutics, Inc. Common Stock's current assets represent 78.0% of total assets in 2025, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 75.3% of total assets in 2025, up from 0.0% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
City Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of City Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.57 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.56 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
LegoChem Biosciences Inc
KQ:141080
|
Korea | ₩652.93 Billion |
City Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.71 | 0.73 | 0.80 |
| Quick Ratio | 2.71 | 0.73 | 0.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $110.93 Million | $-923.00 Million | $-505.00 Million |
City Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between City Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 6.08 |
| Asset Growth Rate (YoY) | 3.0% |
| Total Assets | $149.77 Million |
| Market Capitalization | $911.01 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values City Therapeutics, Inc. Common Stock's assets at a significant premium (6.08x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: City Therapeutics, Inc. Common Stock's assets grew by 3.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for City Therapeutics, Inc. Common Stock (2005–2025)
The table below shows the annual total assets of City Therapeutics, Inc. Common Stock from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $149.77 Million | +3.04% |
| 2024-12-31 | $145.35 Million | -99.31% |
| 2019-12-31 | $21.00 Billion | +2.02% |
| 2018-12-31 | $20.58 Billion | -1.37% |
| 2017-12-31 | $20.87 Billion | -1.32% |
| 2016-12-31 | $21.15 Billion | -1.50% |
| 2015-12-31 | $21.47 Billion | -4.40% |
| 2014-12-31 | $22.46 Billion | +40.27% |
| 2013-12-31 | $16.01 Billion | -4.21% |
| 2012-12-31 | $16.71 Billion | -3.89% |
| 2011-12-31 | $17.39 Billion | +7768.78% |
| 2010-12-31 | $221.00 Million | -81.03% |
| 2009-12-31 | $1.17 Billion | +279.48% |
| 2008-12-31 | $307.00 Million | -56.14% |
| 2007-12-31 | $700.00 Million | -95.29% |
| 2006-12-31 | $14.85 Billion | -1880.58% |
| 2005-12-31 | $-834.00 Million | -- |
About City Therapeutics, Inc. Common Stock
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as re… Read more